NEURALINK CO-FOUNDER'S BIONIC EYE WINS EU APPROVAL

Prima combines a surgically implanted retinal device with specialized glasses to restore vision in patients suffering from AMD, a leading cause of blindness in older adults. The system works by converting images captured by the glasses into electrical signals that stimulate remaining retinal cells. Science Corp joins a growing field of neurotechnology companies developing vision restoration systems. The EU approval marks a significant milestone for the startup, allowing it to initiate patient treatments across European markets. AMD affects millions globally, particularly those over 50. Current treatments slow disease progression but do not restore vision. Prima represents a novel approach to addressing this unmet medical need. The approval follows years of development and testing. Science Corp has not disclosed pricing or details on initial patient numbers, though the company expects to expand access as the technology matures.